Effect of lymphocytotoxicity screening assay on mean peak ANC increment after transfusions of G-CSF–mobilized granulocyte components
Transplant day of granulocyte transfusion . | Peak increment in ANC (cells/μL)4-150 . | Component cell dose4-150 (×1010) . | ||||
---|---|---|---|---|---|---|
s-LCA negative . | s-LCA positive . | P4-151 . | s-LCA negative . | s-LCA positive . | P‡ . | |
+2 | 1358 (109-3220) | 1328 (189-3551) | 0.82 | 5.4 (1.9-9.3) | 5.6 (3.3-8.1) | 0.82 |
+4 | 557 (0-1561) | 505 (250-725) | 0.68 | 7.1 (1.3-16.5) | 6.5 (3.2-10.2) | 0.70 |
+6 | 724 (70-2895) | 246 (0-584) | 0.05 | 8.1 (3.0-14.4) | 8.6 (6.3-10.3) | 0.74 |
+8 | 1079 (0-4100) | 283 (60-844) | 0.06 | 10.7 (5.3-16.5) | 8.7 (1.8-14.2) | 0.30 |
Transplant day of granulocyte transfusion . | Peak increment in ANC (cells/μL)4-150 . | Component cell dose4-150 (×1010) . | ||||
---|---|---|---|---|---|---|
s-LCA negative . | s-LCA positive . | P4-151 . | s-LCA negative . | s-LCA positive . | P‡ . | |
+2 | 1358 (109-3220) | 1328 (189-3551) | 0.82 | 5.4 (1.9-9.3) | 5.6 (3.3-8.1) | 0.82 |
+4 | 557 (0-1561) | 505 (250-725) | 0.68 | 7.1 (1.3-16.5) | 6.5 (3.2-10.2) | 0.70 |
+6 | 724 (70-2895) | 246 (0-584) | 0.05 | 8.1 (3.0-14.4) | 8.6 (6.3-10.3) | 0.74 |
+8 | 1079 (0-4100) | 283 (60-844) | 0.06 | 10.7 (5.3-16.5) | 8.7 (1.8-14.2) | 0.30 |